NasdaqGS:UBX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. More Details


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has Unity Biotechnology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: UBX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: UBX's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

-5.5%

UBX

4.6%

US Biotechs

0.9%

US Market


1 Year Return

-16.4%

UBX

27.2%

US Biotechs

22.1%

US Market

Return vs Industry: UBX underperformed the US Biotechs industry which returned 27.2% over the past year.

Return vs Market: UBX underperformed the US Market which returned 22.1% over the past year.


Shareholder returns

UBXIndustryMarket
7 Day-5.5%4.6%0.9%
30 Day41.4%13.2%10.2%
90 Day98.4%16.2%9.7%
1 Year-16.4%-16.4%29.3%27.2%24.8%22.1%
3 Yearn/a26.4%19.9%48.6%38.7%
5 Yearn/a15.9%8.0%99.6%77.6%

Long-Term Price Volatility Vs. Market

How volatile is Unity Biotechnology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Unity Biotechnology undervalued compared to its fair value and its price relative to the market?

3.24x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate UBX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate UBX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: UBX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: UBX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate UBX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: UBX is good value based on its PB Ratio (3.2x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Unity Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

11.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: UBX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: UBX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: UBX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if UBX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if UBX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: UBX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Unity Biotechnology performed over the past 5 years?

-24.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: UBX is currently unprofitable.

Growing Profit Margin: UBX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: UBX is unprofitable, and losses have increased over the past 5 years at a rate of 24% per year.

Accelerating Growth: Unable to compare UBX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: UBX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.8%).


Return on Equity

High ROE: UBX has a negative Return on Equity (-94.07%), as it is currently unprofitable.


Next Steps

Financial Health

How is Unity Biotechnology's financial position?


Financial Position Analysis

Short Term Liabilities: UBX's short term assets ($135.7M) exceed its short term liabilities ($16.9M).

Long Term Liabilities: UBX's short term assets ($135.7M) exceed its long term liabilities ($59.9M).


Debt to Equity History and Analysis

Debt Level: UBX's debt to equity ratio (24.8%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if UBX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: UBX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if UBX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Unity Biotechnology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate UBX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate UBX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if UBX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if UBX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of UBX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

  • Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

4.9yrs

Average management tenure


CEO

Anirvan Ghosh (56 yo)

0.75

Tenure

Dr. Anirvan Ghosh, Ph.D. serves as Chief Executive Officer and Director of Unity Biotechnology, Inc. since March 30, 2020. Dr. Ghosh had been Senior Vice President of Research and Early Development at Biog...


Leadership Team

NamePositionTenureCompensationOwnership
Nathaniel David
Co-Founder9.08yrsUS$1.61m4.32%
$ 13.7m
Anirvan Ghosh
CEO & Director0.75yrno data0.057%
$ 180.3k
Jan van Deursen
9.92yrsno datano data
Judith Campisi
9.92yrsno datano data
Daohong Zhou
9.92yrsno datano data
Lynne Sullivan
Chief Financial Officer0.33yrno datano data
Douglas Rich
Senior Vice President of Operations3.67yrsno datano data
Alexander Azoy
VP of Financeno datano datano data
Daniel Marquess
Chief Scientific Officer5yrsno data0.65%
$ 2.1m
Camille Landis
Senior Vice President of Corporate Development2.58yrsno datano data
Susan Smuck
Senior Vice President of People4.92yrsno datano data
Jamie Dananberg
Chief Medical Officer4.92yrsUS$951.85k0.78%
$ 2.5m

4.9yrs

Average Tenure

52.5yo

Average Age

Experienced Management: UBX's management team is considered experienced (4.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Nathaniel David
Co-Founder9.08yrsUS$1.61m4.32%
$ 13.7m
Anirvan Ghosh
CEO & Director0.75yrno data0.057%
$ 180.3k
Robert Taylor Nelsen
Independent Director9.08yrsUS$212.58k0%
$ 0
Camille Samuels
Independent Director5.75yrsUS$220.08k0.019%
$ 61.1k
Paul Berns
Lead Independent Directorno dataUS$255.08k0.0062%
$ 19.6k
Keith Leonard
Chairman4.92yrsUS$3.27m1.63%
$ 5.2m
Kristina Burow
Independent Director9.08yrsUS$221.58k0.21%
$ 679.1k
Graham Cooper
Independent Director3.67yrsUS$232.58k0.16%
$ 509.3k
David Lacey
Independent Director2.83yrsUS$230.58k0%
$ 0
Margo Roberts
Independent Director2yrsUS$221.58k0%
$ 0

4.9yrs

Average Tenure

54.5yo

Average Age

Experienced Board: UBX's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.2%.


Top Shareholders

Company Information

Unity Biotechnology, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Unity Biotechnology, Inc.
  • Ticker: UBX
  • Exchange: NasdaqGS
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$318.008m
  • Shares outstanding: 52.91m
  • Website: https://www.unitybiotechnology.com

Number of Employees


Location

  • Unity Biotechnology, Inc.
  • 285 East Grand Avenue
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
UBXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2018
9U9DB (Deutsche Boerse AG)YesCommon StockDEEURMay 2018
0YC0LSE (London Stock Exchange)YesCommon StockGBUSDMay 2018

Biography

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company’s lead drug candidates include UBX0101 that is in Phase ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/05 00:32
End of Day Share Price2020/12/04 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.